Activation of NF-κB/p65 Facilitates Early Chondrogenic Differentiation during Endochondral Ossification

Marjolein M. J. Caron¹, Pieter J. Emans¹, Don A. M. Surtel¹, Andy Cremers¹, Jan Willem Voncken², Tim J. M. Welting¹*, Lodewijk W. van Rhijn¹*

¹ Department of Orthopaedic Surgery, Caphri School for Public Health and Primary Care, Maastricht University Medical Center, Maastricht, the Netherlands, ² Department of Molecular Genetics, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands

Abstract

Background: NF-κB/p65 has been reported to be involved in regulation of chondrogenic differentiation. However, its function in relation to key chondrogenic factor Sox9 and onset of chondrogenesis during endochondral ossification is poorly understood. We hypothesized that the early onset of chondrogenic differentiation is initiated by transient NF-κB/p65 signaling.

Methodology/Principal Findings: The role of NF-κB/p65 in early chondrogenesis was investigated in different in vitro, ex vivo and in vivo endochondral models: ATDC5 cells, hBMSCs, chicken periosteal explants and growth plates of 6 weeks old mice. NF-κB/p65 activation was manipulated using pharmacological inhibitors, RNAi and activating agents. Gene expression and protein expression analysis, and (immuno)histochemical stainings were employed to determine the role of NF-κB/p65 in the chondrogenic phase of endochondral development. Our data show that chondrogenic differentiation is facilitated by early transient activation of NF-κB/p65. NF-κB/p65-mediated signaling determines early expression of Sox9 and facilitates the subsequent chondrogenic differentiation programming by signaling through key chondrogenic pathways.

Conclusions/Significance: The presented data demonstrate that NF-κB/p65 signaling, as well as its intensity and timing, represents one of the transcriptional regulatory mechanisms of the chondrogenic developmental program of chondroprogenitor cells during endochondral ossification. Importantly, these results provide novel possibilities to improve the success of cartilage and bone regenerative techniques.

Introduction

Chondrogenic differentiation encompasses the commitment and differentiation of chondro-progenitor cells to chondrocytes. In addition to providing articulating joint surfaces with functional cartilage and maintaining cartilage integrity, chondrogenic differentiation plays an essential role during endochondral ossification. Skeletal growth and bone fracture healing depend on endochondral ossification; growth plate chondrocytes or fracture callus chondrocytes originating from mesenchymal progenitors gradually differentiate into mineralized hypertrophic chondrocytes and finally die by apoptosis. The remaining mineralized extracellular matrix provides a molecular scaffold for infiltrating osteoblasts and osteoclasts to adhere to and remodel, setting the stage for de novo bone deposition [1,2,3].

Transcriptional targets of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) have been recognized as key developmental signaling mediators that regulate endochondral ossification. Early bone fracture healing by endochondral ossification depends on a haematoma-induced inflammatory environment [4] and several NF-κB-target genes (e.g. interleukin (IL)-6, tumor necrosis factor alpha (TNFα), cyclooxygenase (COX)2 and inducible nitric oxide synthase (iNOS)) are involved in bone fracture repair [5,6]. Besides its functions in transcriptional regulation of general catabolic inflammatory processes, NF-κB has been linked to skeletal development [7]. Double KO of NF-κB subunits p50 and p52 shows abnormal skeletal development in mice, which was attributed to impaired growth plate function [8]. Recently, NF-κB subunit RelA (p65) was reported to be activated by Nkx3.2 (Bapx1) to control chondrocyte viability [9]. Moreover, RelA was identified as a transcription factor for bone morphogenic protein (BMP)2 [8,10] and Sox9 (SRY (sex determining region Y)-box 9) in mature chondrocytes during endochondral ossification [11]. Sox9 is expressed by chondroprogenitor cells and is indispensable for chondrogenic differentiation [12,13,14]. Sox9 drives the expression of cartilage matrix genes Collagen type II (Col2A1) and Aggrecan cooperatively with L-Sox5 and Sox6 [15,16,17] and as such maintains chondrocyte phenotype. The involvement NF-κB/p65 as indispensable factor during chondrogenic development has been studied in the context of mature...
chondrocytes. However, the mechanisms by which NF-κB/p65 signaling influences early differentiation of chondroprogenitors remains elusive. We hypothesized that the initiation of chondrogenic differentiation is regulated by transient NFκB/p65 signaling. Our data show that during the very first hours of chondroprogenitor differentiation a transient activation of NFκB/p65 occurs which, in part, regulates the transient expression of key chondrogenic controller Sox9 at the early phase of chondrogenesis. This early transient Sox9 induction precedes the induction of Sox9 that is described to be related to late cartilage matrix synthesis [15,16], revealing a novel bi-phasic induction for Sox9 during chondrogenic differentiation. We found indications that through the early Sox9 induction the transient NFκB/p65 activation determines, at least in part, the late stage fate of the chondrogenic differentiation process. Inhibition of NFκB/p65 mediated signaling is accompanied by inhibition of early Sox9 expression and subsequent inhibition of late stage chondrogenesis. In line with these findings, brief early NFκB stimulation using different NFκB activating molecules (LPS, TNFα or BMP2), enhanced chondrogenesis in our in vitro and ex vivo endochondral models. Our findings demonstrate that NFκB/p65 signaling, as well as its intensity and timing, is an important factor in the transcriptional regulation of the early chondrogenic developmental program of chondroprogenitor cells and thereby in part determines endochondral ossification.

Results

Early ATDC5 differentiation is accompanied by a transient activation of NFκB/p65 and expression of Sox9

As a model for endochondral ossification, the murine chondroprogenitor ATDC5 cell line was used [18,19]. Early involvement of NFκB/p65 signaling was assessed by examining subcellular localization of the NFκB subunit p65 [20] (Figure 1A). In proliferating cells (t = 0) p65 was not detectable in the nucleus. However, upon initiation of chondrogenesis a fraction of cytoplasmically localized p65 translocated to the nucleus, which was readily detectable at 30 minutes post-induction of differentiation. The nuclear occupation of p65 peaked between 0.5 and 4 hours and was not detectable anymore after 8 hours (Figure S1). To further verify overall activation of NFκB/p65, expression of NFκB-target genes was measured (Figure 1B). Induction of COX-2, iNOS, II-6 and TNFα mRNAs was detectable between 1 and 4 hours in differentiation and returned to baseline levels around 8 hours. COX-2 and iNOS proteins showed a similar transient expression (Figure 1C). To verify potential cross-talk between the differentiation program and the early NFκB/p65 response, expression of Sox9 was determined. During ATDC5 differentiation Sox9 expression was transiently induced at 1–4 hours in differentiation and steadily increased again from day 7 in differentiation (Figure 1C). Remarkably, these data imply that the expression of Sox9 during chondrogenic differentiation in ATDC5 is bi-phasic. Confirming completion of the chondrogenic differentiation program in the ATDC5 cells chondrogenic markers Col2A1, Col10A1, and RunX2 increased in expression from day 7 in differentiation (Figure 1D).

Previously it was reported that an NFκB/p65 transcription factor binding site is located in the Sox9 gene [11]. In silico screening of Sox9 promoter regions detected two other putative evolutionary conserved NFκB/p65 transcription factor binding sites in various mammals (Figure S2).

Post-natal growth plates contain a pool of dedicated chondroprogenitor cells in the so-called resting zone. During growth plate development, these resting zone cells differentiate into proliferating chondrocytes and are thus responsible for cartilage generation in the growth plate [21]. To verify whether activation of NFκB/p65 can also be detected in early chondrogenesis during endochondral ossification in vivo, the resting- and proliferative zones of 6 week old mice growth plates were analyzed for expression of Sox9, p63 and NFκB/p65-target genes (COX-2 and iNOS) (Figure 1E). As described previously [22], Sox9 expression was detected in the resting zone (RZ) cells as well as in proliferative zone chondrocytes (PZ). Interestingly, Sox9 seems to be more abundantly expressed in the resting zone. Expression of p65 was found in the cytoplasm of RZ cells and was not detectable in the PZ. Also, p65 was found to be localized in the nuclei of several RZ cells. Both the expression of the NFκB/p65-target genes COX-2 and iNOS was found in the RZ.

Overall, these results indicate that an NFκB/p65 signaling response occurs very early in chondrogenic differentiation and correlates with a thusfar unknown early transient induction of Sox9 in ATDC5 cells.

Inhibition of early NFκB/p65 activation leads to impaired chondrogenic differentiation

To functionally determine the role of the early NFκB/p65 activation in relation to initiation of chondrogenic differentiation, nuclear translocation of NFκB was inhibited by TLCK or Parthenolide. Dose-response experiments (data not shown) revealed optimal inhibitor concentrations: 100 μM TLCK or 10 μM Parthenolide efficiently inhibited NFκB nuclear translocation during early ATDC5 chondrogenesis (Figure 2A). In agreement with efficient NFκB inhibition, both TLCK and Parthenolide inhibited COX-2, iNOS and II-6 mRNA expression at 2 hours in differentiation (Figure 2B). We next tested the functional relationship between the early NFκB/p65 response and chondrogenic differentiation. Early Sox9 levels were reduced by both TLCK and Parthenolide (Figure 2B and Figure S3A). Inhibition of NFκB activation by TLCK or Parthenolide resulted in a similar dose-dependent inhibition of late phase (day 14) Col2A1, Col10A1, RunX2 and Sox9 protein expression (Figure 2C). Results were confirmed using the clinically used NFκB inhibitor Sulfasalazine (Figure 2C). To independently verify the effect of pharmacological NFκB/p65 inhibition on Sox9 expression during early chondrogenic differentiation, we genetically targeted NFκB/p65 by RNAi. Transient transfection of a p65 siRNA duplex in ATDC5 reduced p65 mRNA and protein expression at 2 hours in differentiation by ~50% (Figure 2D, upper left set). Expression of COX-2, iNOS and II-6 were also reduced as compared to Mock transfection (data not shown). In good agreement with the results described above, early expression of Sox9 mRNA and protein was significantly reduced by p65 knock-down (Figure 2D, upper right set). To further validate how p65 knock-down affects long term chondrogenic differentiation, p65 mRNA expression was targeted for a longer timeframe by re-transfection of the siRNA duplex. We confirmed efficient knock-down of p65 mRNA at 10 days in differentiation (Figure 2D, upper left and lower left sets). Functionally the p65 knock-down resulted in impaired chondrogenic differentiation (Figure 2D, lower left and lower right). Finally, to test whether the early transient Sox9 induction influences late chondrogenic differentiation we targeted the expression of Sox9 only in the early phase of differentiation by one single Sox9 siRNA transfection, followed by 7 days of differentiation follow-up under normal differentiation conditions. Efficient knock-down of Sox9 mRNA was confirmed at the start of differentiation. At 2 hours in differentiation the early induction of Sox9 was almost completely abolished (Figure 2E, upper panel). At day 4, Sox9 siRNA treatment was not effective anymore, as no difference in Sox9
expression was detectable between conditions. To verify the consequence of this early Sox9 knock-down, the expression of Col2A1 was determined (Figure 2E, lower panel). Col2A1 expression was detectable from day 4 on. At day 4 a significant difference was found between control and the early Sox9 knock-down. This difference was even bigger at day 7, where early Sox9 knock-down lead to an almost abolished expression of Col2A1. Taken together, these results indicate that inhibition of NF-κB/p65 nuclear translocation suppresses the initiation of chondrogenic differentiation, by inhibiting early Sox9 induction and subsequent expression of late chondrogenic markers. This indicates that late phase chondrogenic development and endochondral ossification are, at least in part, regulated by early NF-κB/p65 and Sox9 signaling events.

Figure 1. Early chondrogenic differentiation is accompanied by NF-κB/p65 activation and transient Sox9 expression. A: Nuclear translocation of the NF-κB subunit p65. Total extract (T), cytoplasmic (C) and nuclear (N) fractions were isolated at 0, 0.5, 1 and 2 hours in ATDC5 differentiation. Cytoplasmic marker: α-tubulin, nuclear marker: Histone H3. B: COX-2, iNOS, II-6 and TNFα mRNA expression at 0–24 hours in differentiation (relative to t = 0 and corrected for β-actin). C: Sox9 mRNA expression during chondrogenic differentiation (left panel), Protein expression of Sox9, COX-2 and iNOS at 0–24 hours in differentiation (middle panel) and for Sox9 also at 0, 7, 10 and 14 days in differentiation (right panels). Molecular weight markers (kDa) are depicted on the left of immunoblots and relative quantifications are depicted on top of immunoblots. * = p<0.05. D: mRNA and protein expression of Col2A1, Col10A1, RunX2 during ATDC5 differentiation E: Sections from 6 weeks old mouse growth plates (resting (RZ) and proliferative (PZ) zones) stained for p65, COX-2, iNOS and Sox9. Lower panels show appropriate negative controls. Bars = 50 μm. doi:10.1371/journal.pone.0033467.g001
Late phase ATDC5 differentiation is enhanced by stimulation of early NF-κB/p65 activity.

The association between early NF-κB activity and initiation of chondrogenic differentiation prompted us to test whether stimulation of NF-κB/p65 enhances chondrogenic differentiation. We enforced NF-κB/p65 signaling by supplementing differentiation medium with the NF-κB/p65-activating molecular tools LPS or TNFα. These activating agents were

Figure 2. Inhibition of early NF-κB/p65-activation leads to impaired ATDC5 differentiation. A: Cells were differentiated in the absence (control) or presence of TLCK (100 μM) or Parthenolide (10 μM) and total (T) and nuclear (N) fractions were prepared. NF-κB was detected as p65. B: Expression of COX-2, iNOS, Il-6 and Sox9 mRNAs at 2 hours in differentiation in the presence of TLCK or Parthenolide. Sox9 protein expression was determined from similar samples (right panel set). C: Protein expression at day 14 in differentiation of Col2A1, Col10A1, Sox9 and RunX2 with TLCK (left panel), Parthenolide (right panel) or Sulfasalazine (lower left panel). D: Knock-down (KD) of p65 mRNA and protein at 0, 2 hours and 10 days in differentiation ("Mock" below figures indicates scrambled siRNA and "p65" below figures indicates p65 KD). Upper right set: expression of Sox9 mRNA and protein in p65 KD cells at 2 hours in differentiation. Lower sets: messenger RNA expression of Col2A1 and Col10A1 at 10 days in differentiation of p65 KD cells. * = p<0.05. E: Sox9 mRNA expression at 0, 2 hours and 4 days in differentiation of cells transfected one day prior to differentiation with scrambled (indicated by "Mock") or Sox9 siRNA (indicated by "Sox9") (upper panel). Col2A1 mRNA expression was determined at day 4 and 7 in differentiation (lower panel). * = p<0.05.

doi:10.1371/journal.pone.0033467.g002
added to the differentiating culture during the first 24 hours of differentiation only (the timeframe in which the early NF-kB/p65 activation takes place). At low LPS concentrations (0.1 ng/ml) and TNFα (10 ng/ml), NF-kB/p65 nuclear translocation was slightly enhanced during early chondrogenic differentiation (Figure 3A) and resulted in increased early expression of COX-2, IL-6 and iNOS mRNAs (Figure 3B). Interestingly, increasing NF-kB/p65 activity enhanced the magnitude of transient Sox9 (as well as L-Sox5 and Sox6) expression early in chondrogenic differentiation (Figure 3B and Figure S3A). Interference with NF-kB-signaling by siRNA mediated p65 knock-down attenuated the LPS- and TNFα induced increased Sox9 expression back to Mock-treated differentiation levels (Figure 3C). Moreover, increased Col2A1, Col10A1, Sox9 and RunX2 expression in 24 hour LPS- and TNFα-exposed cells was detected at day 10 and 14 in differentiation (Figure 3D and Figure S3B). Data show that early and short chondrogenic NF-kB/p65-activation positively responds to environmental stimulation of NF-kB/p65, resulting in overall increased chondrogenic potential late in differentiation.

Early transient NF-kB/p65 signaling during endochondral differentiation of primary mesenchymal progenitor cells

To verify the results obtained with the ATDC5 system, similar endochondral differentiation experiments were performed using human bone marrow stem cells (hBMSC). In hBMSCs, Col2A1 and Col10A1 mRNA and protein expression was evident from day 7 to 21 in chondrogenic differentiation (Figure 4C and Figure S4A). Expression of Col1A1 and PPARγ was not upregulated, ruling out osteogenic or adipogenic differentiation from this multipotent cell source during chondrogenic induction (data not shown). In

![Figure 3. Late phase ATDC5 differentiation is enhanced by stimulation of early NF-kB/p65 activity. A: Cells were differentiated in the absence (control) or presence of LPS (0.1 ng/ml) or TNFα (10 ng/ml) and total (T) and nuclear (N) fractions were prepared. NF-kB was detected as p65. B: Expression of COX-2, iNOS, IL-6 and Sox9 mRNAs at 2 hours in differentiation in LPS or TNFα treated cells. Far right panel set: early Sox9 protein expression in LPS or TNFα treated cells. Far right panel set: early Sox9 protein expression in LPS or TNFα treated cells. C: ATDC5 cells were transfected with a p65 siRNA duplex or scrambled ("Mock") siRNA duplex and differentiated in the absence or presence of LPS (0.1 ng/ml) or TNFα (10 ng/ml) for 2 hours. Knock-down of p65 mRNA was confirmed at 0 and 2 hours in differentiation (left panel). Right panel shows Sox9 mRNA expression. D: Protein expression of Col2A1, Col10A1, Sox9 and RunX2 in differentiated ATDC5 cells (14 days) in the presence of LPS (left panel set) or TNFα (right panel set), only during the first 24 hours of differentiation. * p<0.05. doi:10.1371/journal.pone.0033467.g003]
concordance with ATDC5, p65 translocated to the nucleus at 1 hour in hBMSC differentiation and nuclear p65 levels further sustained up to 4 hours (Figure 4A). Analyses showed that hBMSC chondrogenic differentiation of 3 independent isolates is accompanied by transient expression of COX-2 and IL-6 mRNAs at 0–24 hours in hBMSC differentiation. C: Left; Sox9 mRNA expression during hBMSC differentiation, Sox9 protein expression during 0–24 hours in hBMSC differentiation (middle) and Col2A1 mRNA expression during hBMSC differentiation (right). D: Left; COX-2 protein expression at 0, 2, 4 hours in differentiation in the presence of LPS (0.1 ng/ml) or TLCK (100 μM). Right; Sox9 mRNA expression at 4 hours in differentiation in the presence of LPS (black bars) or TLCK (grey bars). E: Col2A1 protein expression in day 21-samples of differentiated hBMSCs. Lanes 1: control condition, Lanes 2: 0.1 ng/ml LPS (only first 24 hours) and lanes 3: 100 μM TLCK. * = p<0.05.
doi:10.1371/journal.pone.0033467.g004

NF-κB/p65 Activity Facilitates Chondrogenesis

Figure 4. Transient NF-κB/p65 signaling during early chondrogenic differentiation of human bone marrow stem cells. Human bone marrow stem cells from three individuals (hBMSC1/2/3) were differentiated into the chondrocyte lineage using monolayer culture. A: Nuclear (N) and total (T) fractions were isolated from 0, 1, 2, 4 hours samples. NF-κB was detected as p65, cytoplasmic marker: α-tubulin. B: Expression of COX-2 and IL-6 mRNAs at 0–24 hours in hBMSC differentiation. C: Left; Sox9 mRNA expression during hBMSC differentiation, Sox9 protein expression during 0–24 hours in hBMSC differentiation (middle) and Col2A1 mRNA expression during hBMSC differentiation (right). D: Left; COX-2 protein expression at 0, 2, 4 hours in differentiation in the presence of LPS (0.1 ng/ml) or TLCK (100 μM). Right; Sox9 mRNA expression at 4 hours in differentiation in the presence of LPS (black bars) or TLCK (grey bars). E: Col2A1 protein expression in day 21-samples of differentiated hBMSCs. Lanes 1: control condition, Lanes 2: 0.1 ng/ml LPS (only first 24 hours) and lanes 3: 100 μM TLCK. * = p<0.05.
doi:10.1371/journal.pone.0033467.g004

NF-κB/p65 activity by low LPS concentrations during the first 24 hours only, enhanced NF-κB/p65-target gene expression, as well as early Sox9 expression (Figure 4D; COX-2 immunoblot; black bars in graph and Figure S4B/C). Coherent with the murine model, human chondroprogenitor cells clearly showed increased expression of Col2A1 at day 21 when exposed to LPS during the first 24 hours in differentiation (Figure 4E; lanes 2) and lower Col2A1 levels in the presence of TLCK (Figure 4E; lanes 3). Taken together, these data show that hBMSC endochondral differentiation also integrates a transient NF-κB/p65 activation during the early initiation of differentiation, ultimately contributing to the outcome of the chondrogenic cell fate.
NF-κB/p65 signaling induces chondrogenic marker gene expression in mesenchymal progenitor cells without the addition of chondrogenic growth factors

The progenitor cell intrinsic NF-κB/p65 activation occurs as a result of environmental differentiation conditions, but positively responds to NF-κB stimulating agents (LPS and TNFα) early in chondrogenic differentiation. We therefore tested whether an NF-κB/p65-activating stimulus alone would be able to facilitate chondrogenic signaling in mesenchymal progenitors, without the addition of other differentiation factors like insulin or TGFβ3. To this end, ATDC5 proliferation medium was supplemented with only LPS (first 24 hours alone) and subsequently cells were cultured in proliferation medium for 10 or 14 days. A brief stimulation with LPS induced NF-κB/p65 activation (data not shown) and, in contrast to the control condition, resulted in a transient Sox9 expression at 2 hours after LPS exposure (Figure 5A, lower left panel) and equal Sox9, Col2A1 and Col10A1 mRNA expression levels (at day 10 and 14) as normal differentiation conditions do in ATDC5 (Figure 5A). However Col10A1 expression in the proliferation condition at 14 days appeared unexpectedly high as compared to the LPS and differentiation conditions. Briefly, findings were verified in hBMSCs. After 21 days culture in proliferation medium (without insulin and TGFβ3), hBMSCs expressed Sox9 very lowly and Col2A1 and Col10A1 were not expressed (Figure 5B), whereas brief stimulation with LPS (0.1 and 0.01 ng/ml) during the first 24 hours only, resulted in robust expression of Sox9, Col2A1 and Col10A1 protein at 21 days (Figure 5B). To further establish the relevance of our findings in tissue involved in endochondral ossification, we adopted an ex vivo periosteal tissue differentiation model for chondrogenesis using chicken embryonal periosteum [23]. Importantly, as a source for mesenchymal progenitor cells, periosteal tissue is directly relevant to the tissue involved in endochondral ossification, supporting a role for p65 in this mechanism. Finally we addressed whether BMP2 might exert its prochondrogenic action early in differentiation through the NF-κB/p65 induced early Sox9 expression. The early Sox9 mRNA expression was targeted by a single Sox9 siRNA transfection (see also Figure 6C) and differentiation was initiated in the presence of BMP2 (first 24 hours alone). As shown in Figure 6E, in the presence of BMP2, Sox9 siRNA transfection resulted in an efficient knockdown of Sox9 mRNA and protein expression at 2 hours in differentiation. The early knock-down of Sox9 under BMP2 treatment at 2 hours in differentiation resulted in impaired Col2A1 expression at 7 days into differentiation. Overall, these results suggest that BMP2 action in the early chondrogenic phase of endochondral ossification may, in part, be explained via the herein described early transient NF-κB/p65 activation and Sox9 expression. These findings may provide a possible in vivo context for the herein described NF-κB/p65 pathway.

Discussion

We here report that chondrogenic differentiation of chondrogenic progenitor cells is, at least in part, determined by early activation of NF-κB/p65 which subsequently contributes to the initiation of chondrogenic differentiation by regulating the early expression of key chondrogenic factor Sox9.

Inflammatory mediators play crucial roles in cartilage degenerative conditions such as rheumatoid arthritis and osteoarthritis [26,27,28]. Most, if not all of these inflammatory mediators are regulated via activated NF-κB pathways. However, recent studies reported that in chondrocytes NF-κB/p65-target genes are not exclusively associated with cartilage degenerative conditions [29]. TNFα was recently described to regulate expression of BMP2 via an NF-κB/p65 dependent mechanism [8,30,31]. Involvement of NF-κB was reported during development of the growth plate [8,10], as well as in preventing apoptosis of maturing chondrocytes via interaction with Nkx3.2 [9]. NF-κB/p65 has been reported to function as a transcription factor for Sox9 in mature chondrocytes [11] and finally, Aung and colleagues provided evidence that OA chondrocytes excrete soluble factors that initiate chondrogenic differentiation of human mesenchymal stem cells [32]. Except for the last study, most of these previous investigations were limited by the use of matured chondrocytes, thereby leaving the question at which chondrogenic stage an imperative nuclear NF-κB/p65

BMP2 activates NF-κB/p65 in early ATDC5 chondrogenic differentiation

LPS and TNFα were used as tools to activate NF-κB/p65. Exceptions left alone (e.g. TNFα in OA and RA), these activators are not known to be present in the cartilaginous environment. We therefore asked whether growth factors may support the initiation of an early NF-κB/p65 activation in the way described herein. BMPs are known to play crucial roles in early mesenchymal condensation by regulating Sox9 expression [24] and contributing to other phases of the endochondral ossification processes. Also, BMP2 has been described to be able to activate NF-κB/p65 in chondrocytes [25]. As shown in Figure 6A, 30 ng/ml BMP2 resulted in increased expression of Col2A1 and Col10A1 in differentiating ATDC5 cells. To verify whether a similar early NF-κB/p65 activation might involve this BMP2 action, we analyzed p65 nuclear translocation. We found that p65 nuclear translocation at 2 hours in differentiation was more increased in the presence of BMP2 as compared to control (Figure 6B). Increased and more prolonged expression of Sox9, COX-2 and iNOS in the first 24 hours of differentiation confirmed downstream NF-κB/p65-activated pathways (Figure 6C). To further establish a role for p65 in this process, ATDC5 cells were transfected with a p65 siRNA duplex or scrambled siRNA duplex and differentiated in the absence or presence of BMP2 (30 ng/ml) (Figure 6D). Knockdown of p65 mRNA was confirmed at 0 and 2 hours in differentiation and increased further with BMP2 stimulation (see also Figure 6C). The BMP2-initiated increased Sox9 and COX-2 mRNA upregulation is inhibited to equal levels as the differentiated control p65 knock-down condition without BMP2 supplementation, supporting a role for p65 in this mechanism. Finally we addressed whether BMP2 might exert its prochondrogenic action early in differentiation through the NF-κB/p65 induced early Sox9 expression. The early Sox9 mRNA expression was targeted by a single Sox9 siRNA transfection (see also Figure 2E) and differentiation was initiated in the presence of BMP2 (first 24 hours alone). As shown in Figure 6E, in the presence of BMP2, Sox9 siRNA transfection resulted in an efficient knockdown of Sox9 mRNA and protein expression at 2 hours in differentiation. The early knock-down of Sox9 under BMP2 treatment at 2 hours in differentiation resulted in impaired Col2A1 expression at 7 days into differentiation. Overall, these results suggest that BMP2 action in the early chondrogenic phase of endochondral ossification may, in part, be explained via the herein described early transient NF-κB/p65 activation and Sox9 expression. These findings may provide a possible in vivo context for the herein described NF-κB/p65 pathway.
Figure 5. NF-κB/p65 activation induces chondrocyte marker gene expression without the addition of chondrogenic growth factors.

A: Col2A1, Col10A1 and Sox9 mRNA expression at 2 hours (Sox9 only), 10 and 14 days in ATDC5 cells, cultured in proliferation medium in the absence (“control”) or presence (first 24 hours) of LPS (black bars). Col2A1, Col10A1 and Sox9 mRNA expression of standard differentiated ATDC5 is shown for comparative purposes (grey bars; “differentiation control”).

B: Sox9, Col2A1 and Col10A1 protein expression in a representative hBMSC sample cultured for 21 days in proliferation medium with 0.1 or 0.01 ng/ml LPS (first 24 hours).

C: Col2A1, Col10A1, Sox9 and aggrecan mRNA expression in cPACs (chicken Periosteum Agarose Culture) cultured in proliferation medium for 7 days in the absence or presence of LPS during the first 48 hours (black bars). Col2A1, Col10A1, Sox9 and aggrecan mRNA expression of cPACs differentiated in standard differentiation medium (containing TGFβ3 and insulin, see also Materials and Methods) is shown for comparative purposes (grey bars). * = p < 0.05.

D: In similar samples from (C) sections (5 μm) from cPACs were stained by Safranin O/Fast green (upper set), for Col2A1 (middle set) and Sox9 (lower set). For Safranin O and Col2A1 stainings: bars = 200 μm for first and third column micrographs and 100 μm for second and fourth column of micrographs. For Sox9 staining, bars = 150 μm for first and third column of micrographs and 100 μm for second and fourth column of micrographs.

doi:10.1371/journal.pone.0033467.g005
Figure 6. BMP2 activates NF-κB/p65 in early ATDC5 chondrogenic differentiation. A: ATDC5 was differentiated for 14 days in the absence or presence of BMP2 (30 ng/ml). Relative mRNA expression of Col2A1 and Col10A1 was determined. B: Cells were differentiated in the absence (control) or presence of BMP2 (30 ng/ml) and total (T) and nuclear (N) fractions were prepared at 2 hours in differentiation. NF-κB was detected as p65. C: Cells were differentiated for 0–24 hours in the absence or presence of BMP2 and expression of Sox9 (left) and NF-κB-targets COX-2 (middle) and iNOS (right) was determined. D: ATDC5 cells were transfected with a p65 siRNA duplex or Mock siRNA duplex and differentiated in the absence or presence of BMP2 for 2 hours. Knock-down of p65 mRNA was confirmed at 0 and 2 hours in differentiation (left). Middle and right graphs show Sox9 and COX-2 mRNA expression, respectively. E: Left panel set: Sox9 KD at mRNA and protein level at 2 hours in differentiation in cells transfected with scrambled (indicated as “Mock”) siRNAs, scrambled siRNAs in the presence of BMP2, or Sox9 siRNAs (indicated as “Sox9”) in the presence of BMP2. Transfection was done the day prior to differentiation and BMP2 treatment was for the first 24 hours only. Right panel: Col2A1 mRNA expression was determined in same experiment at day 7 in differentiation. * = p<0.05.
doi:10.1371/journal.pone.0033467.g006
presence would be required for differentiation. As we made use of cellular differentiation models that initiate chondrogenic differentiation from a progenitor stage onward, our experiments provided the possibility to address the role of NF-κB/p65 activity in a specific chondrogenic phase, while at the same time determining the consequences of NF-κB/p65 activity during subsequent later chondrogenic phases. We found that Sox9 induction during chondrogenic differentiation of chondroprogenitor cells is bi-phasic and is evident during the first hours of differentiation and induced for a second time later on in differentiation. The late Sox9 induction follows chondrocyte matrix expression and is thereby expected to transcriptionally regulate the induction of cartilage matrix genes such as Col2A1 and aggrecan [15,16]. In addition to late Sox9 follows chondrocyte matrix expression and is thereby expected to be involved in Sox9 regulation during early mesenchymal condensation [24]. These previous findings may provide an in vivo context in which the herein described BMP2 mediated NF-κB/p65-driven early Sox9 expression may function. In addition, other studies [8,10] have shown that BMP2 expression itself can be regulated by NF-κB/p65 during late chondrogenesis in maturated chondrocytes, thereby contributing to longitudinal bone growth and preventing apoptosis of these chondrocytes. Therefore, our and previous findings indicate that BMP2 action and regulation might depend on the chondrogenic differentiation status [30].

In conclusion, our data indicate that initiation of chondrogenic differentiation during endochondral development, at least in part, depends on an early activation of NF-κB/p65. The early NF-κB/p65 activation evokes a novel early and transient expression of Sox9, which, together with a late Sox9 induction, contributes to the outcome of the chondrogenic differentiation program of mesenchymal progenitor cells. Our findings complement previously reported NF-κB/p65 involvement in chondrogenic differentiation and provide novel insight into the origin, timing and dynamics of NF-κB/p65-induced gene expression in early chondrogenic differentiation. These data add to an emerging and growing concept [7] where differentiating chondrocytes and endochondral development are regulated by NF-κB/p65-mediated processes and may be used as new leads to modulate chondrogenic differentiation in cartilage and bone regenerative medicine approaches such as the ACI technique [50] and the in vivo bioreactor technique [51,52].

**Materials and Methods**

**ATDC5 cell culture**

ATDC5 cells [18] were cultured in proliferation medium (DMEM/F12 [Invitrogen], 5% FCS (PAA), 1% antibiotic/antimycotic (Invitrogen) and 1% NEAA (Invitrogen)). Differentiation medium comprised proliferation medium supplemented with 10 μg/ml insulin (Sigma, St. Louis, MO, USA), 10 μg/ml transferrin (Roche Applied Science) and 30 nM sodium selenite (Sigma). Cells were plated at 6,400 cells/cm² and the following day chondrogenesis was initiated by changing the proliferation medium to differentiation medium (or proliferation medium in case of data presented in Figure 5). Medium was changed every 2 days and every day from day 10 onwards. To inhibit NF-κB, TLCK (Acros), Parthenolide (Sigma) and Sulfasalazine (Sigma) were used. LPS (Sigma) or TNFα (R&D) were used as NF-κB/p65 activators. BMP2 was used at 30 ng/ml (Sigma). For RNAi-experiments a p65 siRNA duplex (sense: 5'-AGAGGACAUUGAGGUAAUUTT-3', anti-sense: 5'-AUUGACCCUAAGUUGCUCU TT-3'), a Sox9 siRNA duplex (sense: 5'-GACUGAGCAUCUCGCUA UUTT-3', anti-sense: 5'-AUUGAGGAGAGAUGUCUTT-3') and a scrambled siRNA-duplex (indicated by "Mock") were used (Eurogentec). ATDC5 cells were seeded at 25,000 cells/cm² and transfection with siRNAs (100 nM for p65 and 50 nM for Sox9) was performed using ICAfectin 442 (Eurogentec) according to manu-
facturers’ protocol. Cells were cultured for 2 days before chondrogenesis was initiated.

**hBMSC isolation and culture**

Human bone marrow stem cells (hBMSCs) were obtained from residual iliac crest bone marrow aspirate from young, genetically healthy individuals undergoing spinal surgery. The Maastricht University Medical Centre institutional policy on the use of residual human surgical material specifically states that no informed consent is needed in the case of residual surgical material. However an approval from the institutional Medical Ethical Committee (MEC) for the use of this material is required. The MEC approved this study and assigned approval ID: MEC 08-4-056. Human BMSCs were isolated from the aspirate using Ficoll Paque (Amersham). Proliferation medium consisted of DMEM high-glucose (Invitrogen), 10% FCS (ES-grade), 1% antibiotic/antimycotic and 1% NEAA. Passage 5 cells were plated at 30,000 cells/cm² and chondrogenesis was initiated the next day by changing to differentiation medium (proliferation medium supplemented with 1% ITS (Invitrogen), 50 μg/ml L-ascorbic acid-2-phosphate (Sigma) and 1 ng/ml TGFβ3 (R&D) [53]. In experiments for Figure 5B the proliferation medium was changed with proliferation medium. Medium was changed every 2 days. TLCK (Acros) was used to inhibit NF-κB/p65 activation and LPS (Sigma) was used as NF-κB/p65 activator.

**Chicken periostea agarose culture (cPAC)**

Fertilized eggs of Dekalb white chickens (‘t Anker, Ochten, the Netherlands) were placed in a polyhatch incubator (Brinsea) at 39.2°C and at relative humidity of 40%. At embryonic day 16, embryos were removed and sacrificed by rapid decapitation. Incubation period corresponded to embryos at Hamburger and Hamilton stage 42. Periosteum was dissected from tibiae using aseptic techniques. Periostea were embedded in 1% low-melting agarose/0.9% NaCl using procedures described before [23,54]. Proliferation medium (DMEM/F12, 10% FCS, 1% antibiotic/antimycotic, 1% NEAA) was added and incubated overnight at 37°C/5% CO2. The next day, medium was changed with proliferation medium supplemented with or without LPS (Sigma). For the differentiation control, medium was changed to differentiation medium (proliferation medium supplemented with 1% ITS, 50 μg/ml L-ascorbic acid-2-phosphate, 10 ng/ml TGFβ3) with or without TLCK (Acros). Medium was changed every 2 days. Ethical approval by the institutional animal ethical committee was waived for these experiments as institutional regulations state that no approval from an animal ethical committee was needed to perform embryonic chicken experiments.

**Mouse growth plates**

The growth plates were isolated from tibiae of 6 weeks old C57BL/6 mice. These were surplus wildtype mice from another unrelated experiment. This experiment was approved by the Maastricht University animal ethical committee (DEC) and assigned approval ID: DEC 2008-042. The tibiae's were isolated and fixated in formalin. The growth plates were separated from the rest of the tibia and decalcified in 0.5 M EDTA pH 7.8 for 2 weeks. EDTA was refreshed every 2 days. Growth plates were dehydrated and embedded in paraffin. Five micrometer sections were cut and positioned on Superfrost Plus slides for IHC.

**RT-qPCR**

Total RNA was extracted with TRIzol (Invitrogen). Quantity and purity of extracted RNA were determined by UV-spectrometry (Nanodrop, Thermo Scientific). DNA-free total RNA was reverse transcribed to cDNA using standard procedures and random hexamer priming.

Real time quantitative PCR (RT-qPCR) was performed using Mesagene qPCR mastermix plus for SYBR Green (Eurogentec) and an Applied Biosystems ABI PRISM 7300 Sequence Detection System for amplification with the following profile: initial denaturation 10 minutes at 95°C, followed by 40 cycles of amplification (15 seconds at 95°C and 1 minute at 60°C), followed by a dissociation curve. Data were analyzed using the standard curve method and relative quantification of mRNA expression was normalized to a housekeeping mRNA. Primer sequences are depicted in Table S1.

**Immunoblotting**

Cells were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0, 5.0 mM EDTA pH 8.0, 0.5 mM dithiothreitol and 1 mM phenylmethylsulfonylfluoride). Nuclear extracts were prepared by lysis in a buffer containing 20 mM HEPES (pH 7.8), 20 mM KCl, 4 mM MgCl₂, 0.2 mM EDTA (pH 8.0), 1 mM dithiothreitol, 0.2 mM sodiumvanadate, 0.4 mM phenylmethylsulfonylfluoride, 0.3 mg/ml leupeptin and 0.2 mM sodiumfluoride). Nuclei were separated from cytoplasm by centrifugation (16,100 × g) and the nuclear pellet was lysed in RIPA buffer. Extracts were sonicated and protein concentrations were determined using the BCA method (Sigma). Polypeptides were separated by SDS-PAGE and transferred to nitrocellulose membranes by electroblotting. Primary antibodies for immunodetection were anti-Col2A1 (Southern Biotech), anti-Col10A1 (Calbiochem), anti-Sox9 (Abcam), anti-COX-2 (Cayman), anti-iNOS (Abcam), anti-p65 (Santa Cruz Biotechnologies), anti-RuntX2 (MBL) and anti-α-Tubulin (Sigma). Bound primary antibodies were detected with immunoglobulins conjugated with HRP (DakoCytomation) and visualized by ECL, ECL signals were quantified using Biorad Quantity One 4.6.7 software and relative differences, corrected for background and housekeeper, were determined as compared to control conditions or t = 0.

**Immunohistochemistry**

Chicken PAC samples were dehydrated following standard procedures and embedded in paraﬃn. Tissue sections were cut at 5 μm, deparaffinized and rehydrated using standard protocols. Proteoglycans were stained with Safranin-O (0.1%) and counterstained with Fast Green (0.1%). Stained sections were dehydrated and mounted in Histomount (Thermo Shandon). For Sox9, p65, iNOS and COX-2 expression in 6-weeks old mouse growth plate and cPAC, sections were deparaffinized and antigen retrieval was performed by incubation in boiling citrate buffer (1.8 mM citric acid and 8.2 mM tri-sodium citrate) for 30 minutes. For Col2A1 detection in cPAC, sections were digested with 0.4% hyaluronidase (Sigma) for 30 minutes at 37°C. Endogenous peroxidase activity was inactivated and sections were blocked with 10% normal sheep serum. Primary antibodies were: anti-Sox9 (sc-166505; Santa Cruz Biotechnology), anti-p65 (sc-372; Santa Cruz Biotechnology), anti-COX-2 (sc-2023; BD Transduction Laboratories), anti-iNOS (ab3523; Abcam) and anti-Col2A1 (II-1663; Developmental Studies Hybridoma Bank). Similar antibody concentrations were used for negative controls; mouse IgG1 (Dako) for COX-2 and Col2A1, mouse IgG2a (Dako) for Sox9, normal rabbit serum for iNOS and anti-p65 blocking peptide (sc-372P; Santa Cruz Biotechnologies) for p65. After washing in PBS-T, bound antibodies were detected with HRP-labelled secondary antibodies (Dako, EnVision+ System-HRP labelled Polymer). For
visualisation, DAB substrate (Dako) was used. Stained sections were counterstained with Mayer’s Hematoxylin (Dako), dehydrated and mounted in Histomount as described above.

Statistics

In the Figures, bars represent average value of 3 individual experiments (performed in triplicates; 3 x 3 samples) and error bars represent mean ± SEM. Statistical significance (p<0.05) was determined by unpaired two-tailed student t-tests using Graphpad PRISM 5.0.

Supporting Information

Figure S1 NF-kB/p65 nuclear translocation during early ATDC5 differentiation. (DOC)

Figure S2 In silico scan for NF-kB/p65 transcription factor binding sites in the Sox9 promoter. (DOC)

Figure S3 Chondrogenic differentiation is enhanced by stimulation of NF-kB/p65 activity. (DOC)

Figure S4 NF-kB signaling during chondrogenic differentiation of hBMSCs. (DOC)

References

1. Kronenberg HM (2003) Developmental regulation of the growth plate. Nature 423: 332–336.
2. Einhorn TA, Majeska RJ, Rush EB, Levine PM, Horowitz MC (1995) The sphingosine-1-phosphate receptor regulates chondrocyte proliferation. Nature 375: 618–622.
3. Zuscik MJ, Hilton MJ, Zhang X, Chen D, O’Keefe RJ (2008) Regulation of endochondrogenesis and cartilage differentiation by stress. J Clin Invest 118: 429–438.
4. Grundnes O, Reikeras O (1993) The importance of the hematoma for fracture healing in rats. Acta Orthop Scand 64: 349–342.
5. Einhorn TA, Majeska RJ, Rush EB, Levine PM, Horowitz MC (1995) The expression of cytokine activity by fracture callus. J Bone Miner Res 10: 1272–1281.
6. Mountzias PM, Mikos AG (2006) Modulation of the Inflammatory Response for Enhanced Bone Tissue Regeneration. Tissue Eng Part B Rev.
7. Novack DV (2011) Role of NF-kappaB in the skeleton. Cell Res 21: 169–182.
8. Feng JQ, Xing L, Zhang JH, Zhao M, Horn D, et al. (2003) NF-kappaB specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro. J Biol Chem 278: 29130–29135.
9. Park M, Yong Y, Choi SW, Kim JH, Lee JF, et al. (2007) Constitutive RelA activation mediated by NfkappaB2 controls chondrocyte viability. Nat Cell Biol 9: 287–298.
10. Wu S, Flint JK, Rezvani G, De Luca F (2007) Nuclear factor-kappaB/p65 facilitates longitudinal bone growth by inducing growth plate chondrocyte proliferation and differentiation and by preventing apoptosis. J Biol Chem 282: 35698–35706.
11. Ushta M, Saito T, Ikeda T, Yano F, Higashikawa A, et al. (2009) Transcriptional induction of SOX9 by NF-kappaB family member RelA in chondrogenic cells. Osteoarthritis and cartilage/OARS, Osteoarthritis Research Society 17: 1065–1075.
12. Akiyama H, Chaboisier MC, Martin JF, Schell A, de Crombrugghe B (2002) The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 16: 2813–2828.
13. Lefebvre V, Behringer RR, de Crombrugghe B (2001) L-Sox5, Sox6 and Sox9 control essential steps of the chondrocyte differentiation pathway. Osteoarthritis Cartilage 9 Suppl A: S69–75.
14. Lefebvre V, de Crombrugghe B (1998) Toward understanding SOX9 function in chondrocyte differentiation. Matrix Biol 16: 529–540.
15. Han Y, Lefebvre V (2008) L-Sox5 and Sox6 drive expression of the aggrecan gene in cartilage by sequestering binding of Sox9 to a far-upstream enhancer. Mol Cell Biol 28: 4999–5013.
16. Lefebvre V, Huang W, Harley VR, Goodfellow PN, de Crombrugghe B (1997) SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol 17: 2356–2356.
17. Lefebvre V, Li P, de Crombrugghe B (1998) A new long form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. EMBO J 17: 5718–5733.
18. Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B (2002) L-Sox5 and Sox6 drive expression of the aggrecan gene in cartilage by securing binding of Sox9 to a far-upstream enhancer. Mol Cell Biol 20: 4149–4155.
19. Han Y, Lefebvre V, Kock LM, Ravetto A, van Donkelaar CC, Foolen J, Emans PJ, et al. (2010) Tuning the differentiation of periosteum-derived cartilage using biochemical and mechanical stimulations. Osteoarthritis Cartilage 18: 1528–1535.
20. Chen L, Fink T, Zhang XY, Ebbesen P, Zachar V (2005) Quantitative transcriptional profiling of ATDC5 mouse progenitor cells during chondrogenesis. Differentiation 73: 350–363.
21. Haydn MS, Ghosh S (2006) Shared principles in NF-kappaB signaling. Cell 122: 344–362.
22. Abad V, Meyers JL, Weise M, Gafni RJ, Barnes KM, et al. (2002) The role of the resting zone in growth plate chondrogenesis. Endocrinology 143: 1851–1857.
23. Huang W, Zhou X, Lefebvre V, de Crombrugghe B (2000) Phosphorylation of SOX9 by cyclic AMP-dependent protein kinase A enhances SOX9’s ability to transactivate a Col2a1 chondrocyte-specific enhancer. Mol Cell Biol 20: 4149–4158.
24. Kock LM, Ravetto A, van Donkelaar CC, Foolen J, Emans PJ, et al. (2010) Tuning the differentiation of periosteum-derived cartilage using biochemical and mechanical stimulations. Osteoarthritis Cartilage 18: 1528–1535.
25. Yoon BS, Lyons KM (2004) Multiple functions of BMPs in chondrogenesis. J Cell Biol 93: 95–103.
26. Sugimoto K, Matsumi K, Motomura H, Tokoro T, Wang J, et al. (2006) BMP-2 prevents apoptosis of the N1511 chondrocytic cell line through PI3K/Akt-mediated NF-kappaB activation. J Bone Miner Metab 24: 411–419.
27. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, et al. (2005) Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434: 64–68.
28. Romas E, Gillespie MT, Martin TJ (2002) Involvement of receptor activator of NF-kappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30: 340–346.
29. Wehling N, Palmer GD, Filipa C, Liu F, Wells JW, et al. (2009) Interleukin-1beta and tumor necrosis factor alpha inhibit chondrogenesis by human mesenchymal stem cells through NF-kappaB-dependent pathways. Arthritis Rheum 60: 801–812.
30. Ulivi V, Giannoni P, Gentili C, Cancrini B, Descalzi F (2008) P50/NF-kB-dependent expression of COX2 during differentiation and inflammatory response of chondrocytes. J Cell Biol 104: 1393–1406.
31. Fukui N, Ikeda Y, Ohnuki T, Hikita A, Tanaka S, et al. (2006) Pro-inflammatory cytokine tumor necrosis factor-alpha induces bone morphogenetic protein-2 in chondrocytes via mRNA stabilization and transcriptional up-regulation. J Biol Chem 281: 27229–27241.
32. Fukui N, Zhu Y, Maloney WJ, Ciolajoi I, Sandell IJ (2003) Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes. J Bone Joint Surg Am 85-A Suppl 3: 39–66.

Figure S5 Connection between early NF-kB/p65 activation and growth factor expression in ATDC5 chondrogenic differentiation. (DOC)

Table S1 DNA oligo sequences for RT-qPCR. (DOC)

Acknowledgments

LPS and surplus mice were provided by Dr. M. Pocez and Drs. N. Wijnands (Dept. of General Surgery, MUMC, the Netherlands) and ParthenoLife by Dr. R. Langen (Dept. of Pathology, MUMC, the Netherlands). P.T. Oosterveen (Dept. of Orthopaedic Surgery, MUMC, the Netherlands) for performing cPAC experiments. Helpful suggestions about the cPAC model were provided by Dr. C.C. van Donkelaar (Dept. of Orthopaedic Biomechanics, Eindhoven University of Technology, Eindhoven, the Netherlands).

Author Contributions

Conceived and designed the experiments: MMJC TJMW PJE LWvR. Performed the experiments: MMJC TJMW DAMS AC. Analyzed the data: MMJC TJMW PJE LWvR. Contributed reagents/materials/analysis tools: LWvR J-JW. Wrote the paper: MMJC TJMW. Revised and approved manuscript: MMJC TJMW PJE LWvR DAMS AC J-JW.
32. Aung A, Gupta G, Majid G, Varghese S (2011) Osteoarthritic chondrocyte-secreted morphogens induce chondrogenic differentiation of human mesenchymal stem cells. Arthritis Rheum 63: 148–158.

33. Baldik Y, Diwan AD, Appleyard RC, Fang ZM, Wang Y, et al. (2005) Deletion of iNOS gene impairs mouse fracture healing. Bone 37: 32–36.

34. Diwan AD, Wang MX, Jang D, Zhu W, Murrell GA (2000) Nitric oxide modulates fracture healing. J Bone Miner Res 15: 342–351.

35. Franchimont N, Durant D, Canalès E (1997) Interleukin-6 and its soluble receptor regulate the expression of insulin-like growth factor binding protein-5 in osteoblast cultures. Endocrinology 138: 3380–3386.

36. Gerstenfeld LC, Cho TJ, Kon T, Aizawa T, Cruceta J, et al. (2001) Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling. Cells Tissues Organs 169: 285–294.

37. Gerstenfeld LC, Cho TJ, Kon T, Aizawa T, Tsay A, et al. (2003) Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res 18: 1584–1592.

38. Naik AA, Xie C, Zuscik MJ, Kingley P, Schwarz EM, et al. (2009) Reduced COX-2 expression in aged mice is associated with impaired fracture healing. J Bone Miner Res 24: 251–264.

39. Rundle CH, Wang H, Yu H, Chadwick RB, Davis EI, et al. (2006) Microarray analysis of gene expression during the inflammation and endochondral bone formation stages of rat femur fracture repair. Bone 38: 521–529.

40. Simon AM, O'Connor JP (2007) Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. J Bone Joint Surg Am 89: 500–511.

41. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, et al. (2002) Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109: 1405–1415.

42. Zhu W, Murrell GA, Lin J, Gardiner EM, Diwan AD (2002) Localization of nitric oxide synthases during fracture healing. J Bone Miner Res 17: 1470–1477.

43. Criostomo PR, Wang Y, Markel TA, Wang M, Lahn T, et al. (2008) Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B–but not JNK-dependent mechanism. Am J Physiol Cell Physiol 294: C675–682.

44. Wang M, Criostomo PR, Herring C, Meldrum KK, Meldrum DR (2006) Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 291: R880–884.

45. van der Kraan PM, van den Berg WB (2007) Osteophytes: relevance and biology. Osteoarthritis Cartilage 15: 237–244.

46. Grau AM, Datta PK, Zl J, Halder SK, Beauchamp RD (2006) Role of Smad proteins in the regulation of NF-kappaB by TGF-beta in colon cancer cells. Cell Signal 18: 1041–1050.

47. Wu S, Fadoju D, Rezvani G, De Luca F (2008) Stimulatory effects of insulin-like growth factor-I on growth plate chondrogenesis are mediated by nuclear factor-kappaB p65. J Biol Chem 283: 58037–58044.

48. Croitoro-Lamoury J, Lamoury FM, Zaunders JJ, Veas LA, Brew BJ (2007) Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research 27: 53–64.

49. Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousse-Noori L, Zanin-Zhorov A, et al. (2007) Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109: 1422–1432.

50. Britberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, et al. (1994) Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 331: 889–895.

51. Emans PJ, van Rhijn LW, Welting TJ, Cremers A, Wijnands N, et al. (2010) Autologous engineering of cartilage. Proc Natl Acad Sci U S A 107: 3418–3423.

52. Stevens MM, Marini RP, Schafer A, Aronson J, Langer R, et al. (2005) In vivo engineering of organs: the bone bioreactor. Proc Natl Acad Sci U S A 102: 11450–11455.

53. Schallmoser K, Rohde E, Reinisch A, Barmann G, Thaler D, et al. (2008) Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods 14: 185–196.

54. O’Driscoll SW, Recklies AD, Poole AR (1994) Chondrogenesis in periosteal explants. An organ culture model for in vitro study. J Bone Joint Surg Am 76: 1042–1051.